Amico Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 29 Days
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.00 M
- Revenue Growth 15.65%
- Profit Growth 34.30%
- Ebitda 17.15%
- Net Worth 53.22%
- Total Assets 210.04%
About Amico Pharmaceuticals
Amico Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 January 2012 and has a history of 13 years. Its registered office is in Thane, Maharashtra, India.
The Corporate was formerly known as Amico Pharmacuitical Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Indira Ranjan and Mani Ranjan serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U36100MH2012PTC226495
- Company No.
226495
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jan 2012
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Amico Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Indira Ranjan  | Director | 27-Jan-2012 | Current |
| Mani Ranjan | Director | 27-Jan-2012 | Current |
Financial Performance of Amico Pharmaceuticals.
Amico Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 15.65% increase. The company also saw a substantial improvement in profitability, with a 34.3% increase in profit. The company's net worth Soared by an impressive increase of 53.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amico Pharmaceuticals?
Unlock access to Amico Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Vijaya Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Sep 2017 | Vijaya Bank | ₹1.00 M | Open |
How Many Employees Work at Amico Pharmaceuticals?
Unlock and access historical data on people associated with Amico Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amico Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amico Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.